Immunome IMNM Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $14.22M+21.3% | $11.72M+2.1% | $11.48M-6.1% | $12.22M-6.2% | $13.03M+1.5% | ||
| $4.02M-42.2% | $6.94M-28.3% | $9.68M-23.1% | $12.59M+15.1% | $10.94M+21.0% | ||
| $186.8M+5.4% | $177.29M+1.7% | $174.41M+7.4% | $162.41M+7.5% | $151.05M+16.6% | ||
| $46.03M+5.2% | $43.77M+3.9% | $42.12M+3.5% | $40.7M+8.1% | $37.64M+14.2% | ||
| $242.82M+5.1% | $231.05M-5.3% | $243.9M+2.8% | $237.2M+3.5% | $229.08M-27.2% | ||
| -$238.81M-6.6% | -$224.11M+4.3% | -$234.22M-4.3% | -$224.61M-3.0% | -$218.14M+28.7% | ||
| -5,947.9%-2,719pp | -3,228.8%-809pp | -2,419.9%-636pp | -1,784.1%+210pp | -1,994.3%+1,388pp | ||
| -$224.59M-5.7% | -$212.39M+4.6% | -$222.74M-4.9% | -$212.39M-3.5% | -$205.11M+30.0% | ||
| -5,593.8%-2,534pp | -3,060%-759pp | -2,301.3%-614pp | -1,687.1%+188pp | -1,875.2%+1,365pp | ||
| -$2.38+1.7% | -$2.42+18.0% | -$2.95+4.2% | -$3.08+3.1% | -$3.18+38.5% | ||
| -$236.35M-6.6% | -$221.65M+4.4% | -$231.94M-4.2% | -$222.5M-3.0% | -$216.12M+29.0% | ||
| -5,886.7%-2,693pp | -3,193.3%-797pp | -2,396.3%-629pp | -1,767.4%+208pp | -1,975.8%+1,389pp | ||
| -$238.81M-6.6% | -$224.11M+4.3% | -$234.22M-4.3% | -$224.61M-3.0% | -$218.14M+28.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Where does Immunome's income statement data come from?
- Every line is extracted from Immunome's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.